




Ped. Acute Liver Failure

Dr. Shiva Mohammadi

Fellowship of Pediatric Gastroenterology



Mofid Children's Hospital
Shahid Beheshti University of Medical Sciences



Dr. Shiva Mohamadi

Subspeciality Resident of Gastroenterology and Hepatology

Mofid Hospital



Introduction

Pediatric ALF is *not* a single diagnosis.

Pediatric ALF is a *complex, rapidly progressive* clinical syndrome.

Is the *final* common pathway for many disparate conditions.



Frequency in all age groups in the USA **17/ 100 000/ yr.**

Frequency in children is *unknown*.

ALF accounts for **10 - 15% of ped. Liver transplants performed annually.**

Management requires a *multidisciplinary team*.



Pressing clinical questions:

Is the condition treatable?

Risk of deterioration or improvement on each day the child is alive with his/her *native* liver?

Possibility of the full recovery **without** a liver **transplantation**.

Are associated morbidities recoverable or irreversible?



Definition of ped. ALF

In adults

First signs of hepatic dysfunction -----HE



Less than 8 weeks

In children

1. HE is **difficult to assess** in children and may not be clinically apparent until the terminal stages of the disease process.
2. In setting of ALF **mental status changes** caused by infection, metabolic derangements, anxiety associated with acute illness is not discernable from liver – based encephalopathy.
3. The **onset of jaundice** is a time point that is **difficult to define** as it is dependent on clinical observation by individuals with disparate expertise in assessing jaundice. And jaundice may go undetected for a period of time.



Entry criteria

1. Children with **no** known evidence of **chronic** liver disease
2. **Biochemical** evidence of **acute** liver injury
3. **Coagulopathy not corrected** by vitamin K
 - **PT: 15 (20 without HE)**
 - **INR : 1.5 (2.0 without HE)**



Clinical Characterization

A **previously healthy** patient typically experiences a **non-specific** prodrome include :

Abdominal discomfort .x

Malaise .۲

Fever +/- .۲



Symptomes :

- **Persist**
- **Wax and wane**

Precise onset of disease is rarely identified (unless acute ingestion of e.g mushrooms, acetaminophen...)

Etiology

- **Acetaminophen**
- **Medication (non-acetaminophen) or toxin**
- **Immune dysregulation**
 1. **Autoimmune marker positive**
 2. **Hemophagocytic lymphohistiocytosis**
 3. **Neonatal hemochromatosis**



- **Inherited metabolic disease**
- **Infectious diseases**
 - 1. Hepatitis viruses**
 - 2. Infection with viruses other than hepatitis viruses**

3. Non-viral infectious hepatitis :

- a) *Nisseria meningitides*
- b) Septic shock
- c) Intra-abdominal abscesses
- d) Portal sepsis with enteric organisms
- e) Spirochetal infection
- f) Congenital syphilis
- g) Leptospirosis
- h) Brucella spp
- i) *Coxiella burnetii* (Q fever)
- j) Plasmodium falciparum
- k) **EH (Entamoeba Histolytica)**



- **Indeterminate failure (50%)**

نکته های استامینوفن

از هر بیمار مبتلا به نارسایی حاد کبد باید تاریخچه مصرف استامینوفن سوال شود :

- ۱- یا به تنهایی دریافت شده یا در همراهی با دکونژستان ها / ناركوتیک ها.
 - ۲- گاه حتی در دوزهای درمانی می تواند هپاتوتوکسیک باشد.
 - ۳- ممکن است با مصرف تعدی تک دوز هپاتوتوکسیک (< 100 میلیگرم / کیلوگرم) مواجه باشیم یا مصرف غیر عمدی.
 - ۴- گاهی مصرف مزمن استامینوفن مطرح است در دوزهای 100 میلیگرم / کیلوگرم / روزانه.
 - ۵- از مصرف همزمان سایر هپاتوتوکسیک ها هم باید پرسید.
- ☀ دو کلید هپاتوتوکسیسیته استامینوفن :

آنزیم ها در حد 10000 بالا می روند اما افزایش بیلروبین نهایت تا 10 است.

در بیوپسی کبد ، نکروز سنتری لوبولر داریم.



کلیدهای بیوپسی داروهای غیر استامینوفن

- 1. Drug induced hepatitis: INH , PTU , Halothane**
- 2. Cholestasis : Oxacillin**
- 3. Steatosis : Sodium valproate , Amiodarone**
- 4. Mixed hepatitis + cholestasis : Sulfa drugs**



HLH Criteria (5 of 8)

Clinical Criteria :

- Fever (> 7 ds)**
- Splenomegaly**

Laboratory Criteria:

Bicytopenia without marrow hypoplasia , including:

HGB < 9

Plt < 100 000

PMN < 1000

TG >/= 265 and/or Fibrinogen </= 150

Hemophagocytosis in the BM, spleen or LN without evidence of malignancy

Low or absent NKC cytotoxicity

Ferritin >/= 500 ng/MI

Elevated soluble CD25 (IL-2R α chain; >/= 2400U/MI)



Ethiology of ALF In < 3mo

1. HSV blood PCR (or HSV IgM, viral culture of blood or CSF, CSF PCR)
2. Enterovirus PCR
3. Lactate, Pyruvate (mitochondrial dis.)
4. Plasma Acylcarnithin Profile (FAOD)
5. Ferritin(Neonatal ISD Screen)
6. Serum AA profile (UCD/Metabolic)
7. Confirm newborn screen results (Galactosemia)
8. Confirm maternal HBV serology
9. Echocardiography and Abdominal US & Doppler (Vascular/Anatomic)



Ethiology of ALF In 3mo-4yr

1. HBS Ag, HAV IgM, EBV (VCA IgM or EBV PCR)
2. Lactate, Pyruvate (Mitochondrial dis.)
3. ANA, ASMA, ALKM, IgG (AutoImmune Hepatitis)
4. Drug Hx and Acetaminophen level
5. Plasma Acylcarnithine Profile (FAOD)
6. Serum AA Profile
7. Abdominal US & Doppler



Ethiology of ALF In 5yr-18yr

1. HBSAg, HAV IgM, EBV (VCA IgM or PCR)
2. ANA, ASMA, ALKM, IgG (AIH)
3. Ceruloplasmin (WD)
4. Drug Hx, Acetaminophen level
5. Lactate, Pyruvate (Mitochondrial)
6. Plasma Acylcarnithine Profile (FAOD)
7. Serum AA Profile
8. Abdominal US & Doppler

Metabolic Dis. Presenting as ALF <6mo

1. Galactosemia ----- Urine RS

2. Neimann-Pick Type C ----- Filter paper

در گیلان، مازندران، ایلام و لرستان دیده می شود/آتوزومال مغلوب است و در ازدواجهای فامیلی اتفاق می افتد.

1. Tyrosinemia ----- HPLC/USA

2. Glycosilation Defect -----

3. Mitochondrial Dis. ----- Lactate, Pyruvate

در ماه های نخستین عمر موارد متابولیک که منجر به نارسایی حاد کبد می شوند شامل گالاکتوزمی، تیروزینمی، میتوکندریال و نیمن پیک هستند.

☀️ کلید گالاکتوزمی = تاریخچه مصرف شیر واجد لاکتوز + سپسیس گرم منفی + مواد احیاکننده در ادرار + نارسایی حاد کبدی.

☀️ کلید تیروزینمی = کوآگولوپاتی + سپسیس گرم منفی + آمینوترانسفراز نرمال یا نزدیک به نرمال

☀️ کلید هیپاتوپاتی میتوکندریال = نقایص نرولوژیک پیشرونده + کاردیومیوپاتی + میوپاتی + لاکتیک اسیدوزیس + نسبت لاکتات به پیرووات < ۲۵ مول / مول

☀️ کلید نیمن پیک = اسپلنومگالی



Metabolic Dis. Presenting as ALF In 7mo-4yr

1. Mitochondrial ----- Lactate, Pyruvate
2. Tyrosinemia ----- HPLC/USA
3. **Alpha-1 AT Defficiency** ----- Alpha-1AT
(Genotype/Phenotype)
4. Hereditary Fructose Intolerance ---- Urine RS
5. Urea Cycle Defect ----- BUN/HPLC

در بچه های شیرخوار بزرگتر و کودکان تا ۵ سالگی بیشتر اختلالات سیکل اوره ، تیروزینمی ، میتوکندریال و عدم تحمل ارثی فروکتوز مطرح اند.

☀️ کلید اختلالات سیکل اوره = هایپرامونمی + تغییرات وضعیت منتال + تشنج +
اما میبینید که تست های فانکشن کبد خوبند (یعنی ظن هپاتیک انسفالوپاتی
نمی رود.)

☀️ کلید عدم تحمل ارثی فروکتوز = زمان شروع علایم است که بعد از شروع
فروکتوز و سوکروز است و نه زودتر.



Metabolic Dis. Presenting as ALF In 5-18yr

- 1. Wilson Disease** ----- Ceruloplasmin
- 2. Mitochondrial** ----- Lactate, Pyruvate
- 3. Fatty Liver of Pregnancy** ----- LFT

در سنین بالای ۵ سال شایعترین بیماری متابولیک همراه با نارسایی حاد کبد ، **ویلسون** است. اما اختلال **اکسیداسیون اسیدهای چرب** هم ذکر شده.
☀️ کلید های ویلسون : آنمی همولیتیک کومبس منفی + هایپر بیلیروبینمی +
آلکالین فسفاتاز کاهش یافته + سرولوپلاسمین کاهش یافته سرم

In adults :

Alp : Bil < 4 and AST : ALT > 2.2



Diagnostic approach

Hx

- Onset of symptoms such as jaundice
- Change in mental status
- Easy bruising
- Vomiting
- Fever



- **Exposure to contact with infectious hepatitis**
- **Hx of blood transfusions**
- **Prescription and over – the – counter medications in the home**



- **F/H of:**
 1. **Wilson disease**
 2. **α-1 AT deficiency**
 3. **infectious hepatitis**
 4. **infant deaths**
 5. **or autoimmune conditions**
- **Evidence of NDD/seizures**


- Evidence of a chronic liver condition with an acute presentation:
 1. Pruritus
 2. Ascites
 3. Growth failure

Ph/Ex

- Evaluation of growth/ development/ nutrition status
- Evidence of jaundice/ bruises/ bleeding following venipuncture/ petechiae
- Hepatomegaly +/- splenomegaly/ ascites/ peripheral edema
- Kayser-Fleischer rings are present in only **50%** of patients with **Wilson disease** who present with ALF
- Fetor hepaticus associated HE is rarely present

- **Stigmata of chronic liver disease = Long-standing portal HTN =
Include:**
 - 1. Digital clubbing**
 - 2. Palmar erythema**
 - 3. Cutaneous xanthoma**
 - 4. Prominent abdominal vessels**
- **Altered mental status should be assessed but may be difficult to assess in infants and young children.**



Skin and extrimities: Jaundice, flushing or pallor, palmar erythema, spider angiomas, digital clubbing, terry nails



Abdomen: Distention, caput medusa, ascites, shrunken liver, large spleen, rectal varices



Collaterals in cirrhosis





Lab. Tests

- **General tests to hematological, renal, pancreatic, and electrolyte abnormalities**
- **Liver-specific tests to assess the degree of**
 - 1. Inflammation**
 - 2. Injury**
 - 3. Function**
- **Dignostic tests**

Complications/Hematologic

- PT and INR:
 1. To assess the **severity of liver injury**
 2. **But no the risk of bleeding**
 3. Because of balanced reduction in the pro(Factors 5, 7, 10, fibrinogen)
 4. and anticoagulant proteins(Pr.C, S, antithrombin)
 5. **Infrequency of clinically important bleeding in ALF** in the absence of **provocative** event such as infection and portal HTN is
 6. So FFP transfusion or recombinant factor 7 should occur primarily in the setting of **active bleeding** or before invasive surgical **procedure**
 7. Iv infusion of **vit. K**

- **Aplastic anemia**

1. Bone marrow failure => mild pancytopenia to aplastic anemia

2. Is identified most commonly in the setting of indeterminate ALF

3. May not be clinically evident until after emergency liver transplantation

4. Tx = immunomodulatory medications:

❖ CS



Complications/ GI Tract

- Ascites

1. Some but **not all** patients
2. Precipitating factors:
↓Alb, ↑fluid administration, **infection**

Tx:

1. Fluid restriction
2. Diuretic should be reserved for patients with:
 - ❖ Respiratory compromised
 - ❖ Generalized fluid overload(Overy aggressive diuresis => **Hepatorenal** syndrome)

- **Bleeding**

1. Prophylactic acid reducing agents is often initiated but their usefulness is difficult to assess.

1. Causes:

- ❖ **Gastric erosions/ulcers (due to CS or idiopathic G/DU)**
- ❖ **Infection (So B/C and AB should be considered when GIB develops)**

2. Transfusion of PLT, PC, and FFP: If GIB is hemodynamically significant.



- **Pancreatitis**

1. Is associated with **multisystem failure** in critically ill children.
2. **Glucose and fluid** management is more significant.



Complications/Renal system

- 1. Renal insufficiency** (because of medication or toxin)
- 2. Prerenal azotemia**(Secondary to excessive fluid restriction, systemic hypotension in sepsis or hemorrhage)
- 3. Hepatorenal syndrome** (in chronic liver diseases)
- 4. Simultaneously renal failure and ALF in toxic injury**(acetaminophen, solvent, drugs)



HRS (Hepato Renal Syndrome)

Splanchnic vasodilation → decrease effective blood volume → (+)R-A-A →

- ▶ Decrease renal perfusion
- ▶ Ald↑ → Na retention



- **Oliguria [$UO < 1\text{cc/kg/h}$]**
- **U.Na < 10**
- **FENa < 1%**
- **U.Cr/Serum.Cr < 10 [U:P Cr ratio]**
- **Normal U.Sedimentation**
- **No hypovolemia**
- **R/O other renal pathologies**

Complications/Metabolic disorders

- Hypoglycemia

1. ↓ Gluconeogenesis, ↓ glycogen stores

2. Glucose infusion rate as high as **10-15 mg/kg/min** may be required.

$$[\text{cc/kg} \times \% \text{ Dextrose}] \div 144 = \text{mg/kg/min}$$



- **Hypokalemia**

1. Dilutional

2. Ascites

3. Renal wasting

- **Hypophosphatemia**

Serum phosphor should be monitored frequently.

- **Acid-base disturbances**

1. Hyperventilation=> resp.alk

2. Respiratory failure=> resp.acidosis

3. Hypokalemia=> met.alk

**4. Hepatic necrosis, anaerobic metabolism, shock=>
met.acidosis**



Complications/Infections

1. Enhanced **susceptibility to bacterial infection** and sepsis from immune dysfunction.
2. Evidence of infection may be **subtle** (tachycardia, intestinal bleeding, ↓renal output, changes in mental status)
3. Fever may not be present
4. Any evidence in clinical deterioration = Obtain **B/C** and initiation **AB**



Complications/Cardiopulmonary system

- **Pulmonary edema**(Secondary to *excessive fluid administration*)
- **Protection:**
 1. Careful **fluid restriction** + discrete use of **diuretics** but with caution
 2. **CVP** monitoring
 3. **Inotropic support**



Complications/ CNS[HE]

- A **neuropsychiatric syndrome** associated with hepatic dysfunction.
- Change in:
 1. Behavior
 2. Cognition
 3. Neurologic examination
 4. EEG

- **HE is not always clinically apparent in infants and young children.**
 - **Distinguishing hepatic-based encephalopathy from other causes of an altered mental status such as :**
 - **Sepsis**
 - **Hypotension**
 - **Electrolyte disturbances**
 - **Anxiety**
 - **ICU psychosis**
- is difficult for all age groups**



- **Hyperammonemia** play a **central role** in the development of **HE** in most cases

Stages of HE (Clinical)

0 --- Non

I --- Infant/Child: Inconsolable crying, Inattention to task, Not acting like self to parents

Adult: Confused, Mood changes, Altered sleep habits, Forgetful

II --- Infant/Child: Like Stage I

Adult: Drowsy, inappropriate behavior, decreased inhibition

III --- Infant/Child: Somnolence, stupor, combativeness

Adult: Stuporous, obey simple commands

IV --- Infant/Child/Adult: Comatose, arouses with painful stimuli (IVa) or no response (IVb)



Stages of HE (DTR)

Infant/Child:

Normal --- Normal or hyper --- Normal or hyper --- Hyper ---
Absent

0

I

II

III

IV

Adult:

Normal --- Normal --- Hyper --- Hyper, Babinski(+) --- Absent

0

I

II

III

IV



Stages of HE (Neurologic Signs)

Infant/Child:

Difficult or impossible to test adequately

I, II, III

Adult:

**Tremor, Apraxia, Impaired hand-writing --- Dysarthria, ataxia ---
Rigidity**

I

II

III

In all age group:

***0: Non**

***IV: Decerebrate/decorticate**



Stages of HE (EEG)

Infant/Child:

Difficult or impossible to test adequately

I, II, III

Adult:

NL/diffuse **slowing(θ)/triphasic w.--- AbNL/generalized **slowing**/triphasic w.**

I

II, III

In all age group:

***0:NL**

***IV: AbNL/**very slow**/ Δ activity ($\Delta=4$)**

نکات بالینی مراحل انسفالوپاتی کبدی

۱. در مرحله ۰ هیچ اتفاقی نیفتاده. (در همه گروههای سنی)
۲. در مرحله ۴ پاسخ به صدا نداشته. پس می رویم سراغ تحریک دردناک. بر اساس پاسخ یا عدم پاسخ به دو دسته آ و ب تقسیم میشود.
۳. در شیرخوار و کودک ۱ و ۲ یکسانند.
۴. در بالغین خوابیدن در روز و بیداری در شب = ورود به مرحله ۱ انسفالوپاتی کبدی، یا یک تغییر خلق و حتی فراموشی یا گیجی.
۵. اما مرحله ۲ در بالغین آنست که کلا خواب آلود شده باشد، یا رفتارهای بی تناسب / مهار گسیخته به هم زده باشد.
۶. هر کلمه ای درعلایم بالینی با « اس » شرع شود محله ۳ است:
Somnolence, Stupor, Simple commands (obey)

Initial treatment of HE

- Minimising excess stimulation
- Reducing protein intake
- Treating suspected sepsis
- Removing sedative medications
- Lactulose(empirically); but lacks evidence of efficacy.
- Bowel “decontamination” with Rifaximin or Neomycin (as a second-tier treatment)
- Sodium benzoate (in adults with cirrhosis)

[↑ICP is seen in HE, but not in all patients]

- **Direct ICP monitoring** is the most sensitive and specific test compared with brain CT, but has more complications .

[Generalized/focal seizures may occur in ALF that can be convulsive or non-convulsive]

- In most cases **Phenytoin is initial treatment.**
- But in refractory seizures our options will be Midazolam infusion, PB, Levetiracetam or Topiramate



Complications/CNS[Brain edema]

- Is **life threatening**
- Occurs most commonly in cases with **stage 3-4 HE**
- Can be **rapidly progressive**
- The **most sensitive** test requires surgical placement of an **ICP monitor**.(But is high **risk** for the patient with an **uncorrectable coagulopathy** with a risk of bleeding between **10-20%**.Activated factor **VII** has made placement of monitors **safer**.

Pathogenesis of cerebral edema:

- Interaction among ammonia, cerebral blood flow, and inflammation.
- Ammonia enters the astrocytes [containing glutamine synthetase]
- Ammonia and glutamate → **glutamine** [A potent **intracellular osmolyte**] → Astrocyte swelling → Cerebral edema → Intracranial HTN.



Mofid Children's Hospital
Shahid Beheshti University of Medical Sciences

- **Inflammatory milieu**
- **Sepsis**
- **Fluid/blood product administration**

Can result in a sudden increased ICP



Management of IC.HTN

- **Maintain O₂Sat>95%**
- **Fluid restriction [85-90% Maint]**
- **Diastolic pressure>40mmHg**
- **Adequate sedation**
- **Empiric AB**



- **Head elevation of 20 to 30 ° and neutral head position**
- **Hypertonic saline [goal: Na between 145-150meq/L]**
- **Monitol [Serum osm < 320mosm/L]**
- **Hypothermia [in adults has been used]**



Nutrition

Avoid a catabolic state

- **Protein:**

1. 1 gr/kg/day (at least)

2. Adjustment may be needed based on serum ammonia



Mofid Children's Hospital
Shahid Beheshti University of Medical Sciences

- **Micronutrients:**

1. In **liver** disease: ↓Cu and Mn

2. In **renal** disease: ↓Cr, Mb, Selenium



• هر انسانی حق دارد به رسالتش شک کند و گاه آن را رها کند ، اما هرگز نباید رسالتش را فراموش کند.

پائولو کوئیلو